Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice

Circulation Journal

Volumn 74, Issue 4, 2010, Pages 798-806

  Hosoya, Maki ^a   Ohashi, Junko ^a   Sawada, Ayuko ^a   Takaki, Aya ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Endothelium dependent relaxation; Endothelium derived hyperpolarizing factor; Microcirculation

Indexed keywords

APOLIPOPROTEIN E; AZELNIDIPINE; COPPER ZINC SUPEROXIDE DISMUTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; HYDRALAZINE; NITROPRUSSIDE SODIUM; OLMESARTAN; PROTEIN KINASE B; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART MUSCLE FIBER MEMBRANE STEADY POTENTIAL; HYPERPOLARIZATION; LONG TERM CARE; MALE; MICROCIRCULATION; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOLIPOPROTEINS E; AZETIDINECARBOXYLIC ACID; BIOLOGICAL FACTORS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, EXPERIMENTAL; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STREPTOZOCIN; TETRAZOLES; VASODILATION;

EID: 77950648451     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0862     Document Type: Article

References (55)

1. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol 1999; 31: 23-37.
2. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: Bringing the concepts together. Trends Pharmacol Sci 2002; 23: 374-380.
3. Félétou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: Where are we now? Arterioscler Thromb Vasc Biol 2006; 26: 1215-1225.
4. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J 2009; 73: 595-601.
5. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401: 493-497.
6. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 2006; 111: 584-595.
7. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-272.
8. Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 2009; 119: 2323-2332.
9. Taylor HJ, Chaytor AT, Evans WH, Griffith TM. Inhibition of the gap junctional component of endothelium-dependent relaxations in rabbit iliac artery by 18-alpha glycyrrhetinic acid. Br J Pharmacol 1998; 125: 1-3.
10. Mather S, Dora KA, Sandow SL, Winter P, Garland CJ. Rapid endothelial cell-selective loading of connexin 40 antibody blocks endothelium-derived hyperpolarizing factor dilation in rat small mesenteric arteries. Circ Res 2005; 97: 399-407.
11. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106: 1521-1530.
12. Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Bio-phys Res Commun 2002; 290: 909-913.
13. Matoba T, Shimokawa H, Morikawa K, Kubota H, Kunihiro I, Urakami-Harasawa L, et al. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. Arterioscler Thromb Vasc Biol 2003; 23: 1224-1230.
14. Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res 2004; 49: 543-549.
15. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996; 28: 703-711.
16. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 1997; 100: 2793-2799.
17. de Wit C, Wölfle SE. EDHF and gap junctions: Important regulators of vascular tone within the microcirculation. Curr Pharm Biotechnol 2007; 8: 11-25.
18. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-974.
19. d'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein E-deficient mice. Stroke 2001; 32: 2658-2664.
20. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009; 73: 411-418.
21. Feletou M, Vanhoutte PM. EDHF: New therapeutic targets? Pharmacol Res 2004; 49: 565-580.
22. Zhang H, Park Y, Wu J, Chen X, Lee S, Yang J, et al. Role of TNF-α in vascular dysfunction. Clin Sci 2009; 116: 219-230.
23. Morikawa K, Matoba T, Kubota H, Hatanaka M, Fujiki T, Takahashi S, et al. Influence of diabetes mellitus, hypercholesterolemia, and their combination on EDHF-mediated responses in mice. J Cardiovasc Pharmacol 2005; 45: 485-490.
24. Fujiki T, Shimokawa H, Morikawa K, Kubota H, Hatanaka M, Talukder MA, et al. Endothelium-derived hydrogen peroxide accounts for the enhancing effect of an angiotensin-converting enzyme inhibitor on endothelium-derived hyperpolarizing factor-mediated responses in mice. Arterioscler Thromb Vasc Biol 2005; 25: 766-771.
25. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006; 55: 466-473.
26. Kennedy JM, Zochodne DW. The regenerative deficit of peripheral nerves in experimental diabetes: Its extent, timing and possible mechanisms. Brain 2000; 123: 2118-2129.
27. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, et al. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest 2003; 112: 1871-1879.
28. Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280: 10284-10289.
29. Gonzalez-Navarro H, Vila-Caballer M, Pastor MF, Vinue A, White MF, Burks D, et al. Plasma insulin levels predict the development of atherosclerosis when IRS2 deficiency is combined with severe hypercholesterolemia in apolipoprotein E-null mice. Front Biosci 2007; 12: 2291-2298.
30. Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H, et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008; 205: 2053-2063.
31. Bauer PM, Fulton D, Boo YC, Sorescu GP, Kemp BE, Jo H, et al. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric oxide synthase. J Biol Chem 2003; 278: 14841-14849.
32. Dudzinski DM, Michel T. Life history of eNOS: Partners and pathways. Cardiovasc Res 2007; 75: 247-260.
33. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15: 6541-6551.
34. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393.
35. D'Uscio LV, Smith LA, Katusic ZS. Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein E-deficient mice. Stroke 2001; 32: 2658-2664.
36. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701.
37. Matsumoto T, Kobayashi T, Wachi H, Seyama Y, Kamata K. Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis 2007; 192: 15-24.
38. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetra-hydrobiopterin. Circulation 2001; 103: 1282-1288.
39. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: Relevance to endothelial dysfunction in hypercholesterolemia. Circ Res 2001; 88: 145-151.
40. Pannirselvam M, Ding H, Anderson TJ, Triggle CR. Pharmacological characteristics of endothelium-derived hyperpolarizing factor-mediated relaxation of small mesenteric arteries from db/db mice. Eur J Pharmacol 2006; 551: 98-107.
41. Dal-Ros S, Bronner C, Schott C, Kane MO, Chataigneau M, Schini-Kerth VB, et al. Angiotensin II-induced hypertension is associated with a selective inhibition of endothelium-derived hyperpolarizing factor-mediated responses in the rat mesenteric artery. J Pharmacol Exp Ther 2009; 328: 478-486.
42. Mukai Y, Shimokawa H, Higashi M, Morikawa K, Matoba T, Hiroki J, et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 2002; 22: 1445-1450.
43. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020.
44. Diederich D, Skopec J, Diederich A, Dai F. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: Role of free radicals. Am J Physiol 1994; 266: H1153-H1161.
45. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: Focus on olmesartan medoxomil. Vasc Health Risk Manag 2009; 5: 301-314.
46. Ono Y, Nakaya Y, Bando S, Soeki T, Ito S, Sata M. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 2009; 50: 73-83.
47. Yao K, Sato H, Sonoda R, Ina Y, Suzuki K, Ohno T. Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. Hypertens Res 2003; 26: 569-576.
48. Yamamoto E, Dong YF, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008; 52: 573-580.
49. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, et al. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 2006; 319: 1081-1087.
50. Suzuki J, Iwai M, Li Z, Li JM, Min LJ, Ide A, et al. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 2005; 23: 1383-1389.
51. Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, et al. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists. Am J Hypertens 2009; 22: 145-150.
52. Jinno T, Iwai M, Li Z, Li JM, Liu HW, Cui TX, et al. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
53. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
54. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840-844.
55. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-605.